Bank of America Reiterates “Underperform” Rating for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ:AMGN – Get Free Report)‘s stock had its “underperform” rating reiterated by Bank of America in a research report issued on Tuesday,Benzinga reports. They presently have a $256.00 price target on the medical research company’s stock. Bank of America‘s target price would indicate a potential downside of 7.79% from the company’s current price. Several […]

Leave a Reply

Your email address will not be published.

Previous post Insight Inv LLC Grows Stock Position in PACCAR Inc (NASDAQ:PCAR)
Next post Bares Capital Management Inc. Lowers Position in WideOpenWest, Inc. (NYSE:WOW)